

Study of ventilator associated pneumonia in tertiary care hospital Nagpur, India

Sarika Kombade^{1*}, Dr.Gopal Agrawal²

¹Assistant Professor, Department of Microbiology Govt. Medical College, Akola-444001. Maharashtra, INDIA.

²Assistant Professor, Department of Microbiology, Indira Gandhi Government Medical College, Nagpur, 400018. Maharashtra INDIA.

Email: spkombade@gmail.com

Abstract

Introduction: Ventilator associated pneumonia (VAP) is a type of nosocomial pneumonia which occurs in patients who receive mechanical ventilation (MV). In India, occurrence of VAP among intensive care unit (ICU) patients varies from 9% to 24%. **Aim:** This study was conducted to determine the incidence rate, bacteriological profile and antibiotic sensitivity pattern of VAP. **Material and method:** Total 245 ICU infected patients who were on MV > 48 hours were studied prospectively in the Department of Microbiology, from Sep. 2009- Dec. 2011. After the clinical diagnosis as per CDC criteria, the endotracheal secretion were collected and processed as per standard microbiological methods and antibiotic sensitivity pattern was recorded. **Result:** Of total 107 clinically and microbiological diagnosed VAP patient, 114 isolates were obtained. Most common Organism isolated are *Pseudomonas aeruginosa* (33.6%), *Acinetobacter spp.*(29.9%), *Klebsiella pneumoniae*.(26.2%) and Gram positive cocci(8.4%). Maximum gram negative isolates were sensitive to imipenem followed by piperacillin-tazobactam and amikacin. All *Staphylococcus* species were sensitive to vancomycin and linezolid. High MDR were obtained. **Conclusion:** Due to the increasing incidence of multidrug-resistant organisms in ICU, early and correct diagnosis of VAP is an urgent challenge for physician. Hence, knowing the local microbial flora causing VAP and effective infection control practices are essential to improve clinical outcomes.

Key Word: Ventilator associated pneumonia, Endotracheal aspirate culture, Multidrug resistant pathogens, Intensive care unit.

*Address for Correspondence

Dr. Sarika Kombade, Assistant Professor, Department of Microbiology Govt. Medical College, Akola-444001. Maharashtra, INDIA.

Email: spkombade@gmail.com

Received Date: 02/02/2015 Revised Date: 20/12/2015 Accepted Date: 16/10/2016

Access this article online	
Quick Response Code:	Website: www.medpulse.in
	DOI:

INTRODUCTION

Ventilator associated pneumonia (VAP) is a type of nosocomial pneumonia which occurs in patients who receive mechanical ventilation (MV) via tracheal or tracheostomy tube.¹ VAP refers to the development of parenchymal lung infection after a patient has undergone intubation and received MV for ≥ 48 hours.² In India, occurrence of VAP among intensive care unit (ICU) patient varies from 9% to 24%. Global crude mortality rate of VAP ranges from 24% to 50%. In VAP due to

highly resistant organisms, the crude mortality can be as high as 76 %.²⁻⁶ The main route for acquiring VAP is gross or micro aspiration of oropharyngeal organisms into the distal bronchi, either directly or secondarily by reflux from the stomach into the oropharynx. Other potential routes are less common, such as haematogenous carriage of microorganisms to the lung from remote sites of local infection (eg, catheter-related bloodstream infections or from the environment, especially from the hands of health care workers) or contaminated respiratory equipment, bronchoscopes, medical aerosols, water or air.⁷ American Thoracic Society subdivides VAP into early onset (within the first 4 days of the hospitalization) and late onset (usually occurring after the 5th hospital day).⁸ Early onset nosocomial pneumonia tends to carry a better prognosis, whereas late onset nosocomial pneumonia tends to be associated with multidrug resistant (MDR) organisms, means it is associated with high mortality rates. VAP requires a rapid diagnosis and initiation of appropriate antibiotic treatment, as there is adverse effect of inadequate antibiotic treatment on patient's prognosis and the emergence of MDR pathogen.⁷ Inadequate antimicrobial therapy, such as inappropriate antimicrobial

coverage, or delayed initiation of antimicrobials has been associated with higher hospital mortality in subjects with hospital acquired pneumonia or VAP.^{3,7} Appropriate antimicrobial treatment of patients with VAP significantly improves outcome, more rapid identification of infected patients and accurate selection of antimicrobial agents to cover the MDR pathogens. Thus this study was conducted to determine the incidence rate, bacteriological profile and antibiotic sensitivity pattern of VAP in intensive care unit (ICU).

MATERIAL AND METHODS

The study was carried out in Department of Microbiology at a tertiary care institute, Indira Gandhi Government Medical College Nagpur, from September 2009 to December 2011. All patients admitted in the ICU who received MV were included in the study. Patients who were on MV for less than 48 hours and those who had developed pneumonia prior to initiation of MV were excluded from the study. The study was approved by the institute ethics committee. Informed consent was obtained from the patient's next of kin.

Microbiological methods

Endotracheal tube (ET) aspirates were collected under aseptic precaution. ET aspirates was serially diluted in sterile normal saline as 1/10, 1/100, 1/1000 and 0.01 ml of 1/1000 dilution was inoculated on 5% sheep blood agar, chocolate agar, MacConkey agar by using 4 mm Nichrome wire loop (Hi-Media, Mumbai, India). After incubation at 37°C in 5% CO₂ incubator for 24 hours, colony count was expressed as number of colony forming units per ml (CFU/ml). The number of CFU/ml is equal to number of colonies on agar plate · dilution factor · inoculation factor. Therefore, the presence of a single colony on the blood agar after inoculating 0.01 ml of 1/1000 times diluted EA was interpreted as more than 10⁵CFU/ml.^{12,13} VAP was diagnosed in patients who

fulfilled both clinical and microbiological criteria. A clinical diagnosis was made with the use of the Modified Clinical Pulmonary Infection Score (CPIS) based on six clinical assessments, each worth zero to two points as shown in Table 1.³ VAP was confirmed microbiologically in patients with quantitative endotracheal aspirate culture indicative of ≥ 10⁵ CFU/ml with a positive Gram stain (>10 Polymorphonuclear cells/ high power field and ≥ 1 bacteria/ oil immersion field). The isolates were identified based on standard bacteriological techniques.⁹ A detailed biochemical testing identified any significant growth and antibiotic sensitivity testing was performed on Mueller–Hinton agar plates by Kirby–Bauer disc diffusion method. Zone diameter was measured and interpreted as per the Clinical and Laboratory Standards Institute (CLSI-2011) guidelines.¹⁰ Suspected extended-spectrum beta lactamases (ESBLs) producing organisms were confirmed by CLSI phenotypic confirmatory test.¹⁰ Detection of plasmid-mediated AmpC was done by the AmpC disk test and the isolates showing reduced susceptibility to carbapenems (imipenem and meropenem) were selected for detection of metallo-beta lactamases (MBLs) enzymes by imipenem-EDTA disk method.¹⁰ For quality control of disc diffusion tests ATCC control strains of *Escherichia coli* ATCC 25922, *Staphylococcus aureus* ATCC 25923 and *Pseudomonas aeruginosa* ATCC 27853 strains were used.¹⁰

RESULT

A total number of 245 patients were included in this study, as they were on mechanical ventilator for more than 48 hours during the study period. Out of 245, only 107 patients were diagnosed as VAP cases based on clinical and microbiological diagnosis criteria. The incidence of VAP in present study was 43.7%.

Table 1: Clinical Pulmonary Infection Score (CPIS) for diagnosis of nosocomial pneumonia³

Sr no.	Criterion	Values	Score
1	Temperature ⁰ C	> 36.5 and < 38.4	0
		38.5 and < 38.9	1
		> 39 and < 36	2
2	Blood leukocyte/μl	>4000 and < 11,000	0
		< 4000 or >11,000	1
		Band forms > 500	2
3	Tracheal secretions	Absence of tracheal secretions	0
		Presence of nonpurulent tracheal secretions	1
		Presence of purulent tracheal secretions	2
4	Oxygenation, Pao ₂ /FiO ₂ mmHg	> 240 or ARDS	0
		< 240 and no evidence of ARDS	2
		No infiltrate	0
5	Pulmonary radiography	Diffused(or patchy) infiltrate	1
		Localized infiltrate	2
		No radiographic progression	0

		Radiographic progression (after CHF & ARDS excluded)	2
		No pathogenic bacteria cultured	0
7	Culture and Gram stain of tracheal aspirate	Pathogenic bacteria cultured	1
		Some pathogenic bacteria seen on Gram stain	1

(ARDS, adult respiratory distress syndrome; CHF congestive heart failure; Pao2/FiO2, ratio of arterial oxygen pressure to fraction of inspired oxygen)

Table 2: General characteristics of 245 mechanically ventilated patients

Type of intensive care unit, n (%)	
Surgical	- 29 (27.1%)
Medical	- 78(72.9%)
Age, median (IQR)	- 48 (51-60)
Gender (female/male)	- 37/70
Previous use of antibiotics, n	- 88 (%)
Early onset VAP < 4 days	- 60 (56.1)
Early onset VAP > 4 days	- 47 (43.9)
Co morbidities, n (%)	
Immunosuppressive state	- 12 (11.2%)
Chronic renal failure	- 6 (5.6%)
Chronic obstructive pulmonary disease	-30 (28.0%)
Diabetes	- 20 (18.7%)
Alcoholism	- 6 (5.6%)
Cancer	- 3 (2.8%)
Chronic heart failure	- 6 (5.6%)
Organophosphorus poisoning	-24 (22.4%)




Figure 1: Distribution of monomorphic and polymorphic flora of 107 VAP patients

Table 3: Bacterial aetiology in VAP cases

Isolates	VAP (n=114)
<i>E. coli</i>	8 (7.5%)
<i>K. pneumoniae</i>	26 (26.2%)
<i>C. freundii</i>	2 (1.9%)
<i>E. cloacae</i>	1 (0.9%)
<i>P. aeruginosa</i>	36 (33.6%)
<i>A. baumannii</i>	32 (29.9%)
<i>S. aureus</i>	9 (8.4%)

Table 3 shows, 33.6% *P. aeruginosa* was commonest aetiological agent in VAP followed by 29.9% *A. baumannii* and 26.2% *K. pneumoniae* isolates

Table 4: Antimicrobial sensitivity of Gram Negative bacilli (n=105)

Drugs	<i>K. pneumoniae</i> n=26(%)	<i>E. coli</i> n=8 (%)	<i>C. freundii</i> n=2 (%)	<i>E. cloacae</i> n=1 (%)	<i>A.baumannii</i> n=32(%)	<i>P. aeruginosa</i> n=36 (%)	Total(n=105)
Ampicillin	0	0	0	0	-	-	0
Amoxyclav	0	0	0	0	-	-	0
Cephalothin	0	0	0	0	-	-	0
Cefuroxime	1 (3.8)	1 (12.5)	0	0	-	-	2(1.9)
Ceftazidime	4 (15.4)	1(12.5)	0	1(100)	3 (9.4)	15 (41.7)	24(22.9)
Cefotaxime	4 (15.4)	1 (12.5)	0	0	2 (6.3)	10 (27.8)	17(16.2)
Cefipime	8 (30.7)	4 (50.0)	2 (100.0)	1 (100)	4 (12.5)	14 (38.9)	33(31.4)
Piperacillin	10 (38.5)	0	1 (50.0)	1(100.0)	6 (18.8)	14 (38.9)	32(30.5)
Piperacillin + tazobactam	14 (53.8)	3 (37.5)	2(100.0)	1(100.0)	19 (59.4)	31 (86.1)	70(66.7)
Imipenem	21 (80.8)	8 (100)	2(100.0)	1(100.0)	20 (62.5)	32 (88.9)	84(80.0)
Gentamicin	9 (34.6)	6 (75)	1 (50.0)	1(100.0)	7 (21.9)	17 (47.2)	41(39.0)
Amikacin	12 (46.2)	6 (75)	1 (50.0)	1(100.0)	15 (46.9)	24 (66.7)	59(56.2)
Tobramycin	4 (15.4)	3 (37.5)	2(100.0)	0	9 (28.1)	10 (27.8)	28(26.7)
Ciproflo-Xacin	8 (30.7)	1 (12.5)	1 (50.0)	1(100.0)	8 (25)	13 (36.1)	32(30.5)

Table 4 shows that maximum gram negative bacilli isolates were sensitive to imipenem (80.0%) followed by piperacillin -tazobactam (47.3%), amikacin (56.2%), and gentamicin (39.0%), All isolates were resistant to ampicillin, amoxyclav, 1st generation cephalosporins.




Figure 2: β lactamase profile of Gram negative bacilli in VAP

Table 5: Antimicrobial sensitivity of gram positive cocci (n= 7)

Drugs	<i>S. aureus</i> n=7 (%)
Penicillin G	0
Cefoxitin	4(44.4)
Erythromycin	0
Gentamicin	7(77.7)
Amikacin	7(77.7)
Tobramycin	2(22.2)
Netillin	1(11.1)
Rifampicin	3(33.3)
Ciprofloxacin	3(33.3)
Vancomycin	9(100.0)

Linezolid	9(100.0)
Chloramphenicol	3 (33.3)
Tetracycline	2 (22.2)
Cotrimoxazole	3 (33.3)
Clindamycin	2 (22.2)

Table 5. shows that all gram positive cocci were 100% sensitive to linezolid and vancomycin. Four (44.4%) isolates of *S. aureus* were found to be sensitive to cefoxitin. 5 (55.5%) isolates of *S. aureus* were found to methicillin resistant by cefoxitin disc diffusion method.

DISCUSSION

VAP is a leading cause of morbidity and mortality in ICU patients, leading to lengthened ICU and hospital stays and higher health care costs.⁷ VAP continues to be an important challenge to the critical care physician and is the most common nosocomial infection among patients with acute respiratory failure. It is difficult to diagnose accurately, and a high index of suspicion is required. The mortality caused by VAP increases if it is caused by resistant bacteria.¹³ The incidence of VAP in our study was 43.7%, which was similar to studies done by Dey *et al* (45.4%).¹⁴ Woske *et al*¹⁵ and Jamaati *et al*¹⁶ reported 40.4% and 48% VAP cases respectively in their studies. Lower incidence rates were reported by Yehia *et al* (33%).¹⁷ Mukhopadhyay *et al*¹⁸ who reported a very high incidence rate of VAP (81.7%). Our study shows that patients in the age group of 51-60 years were more prone to VAP as the number of patients exposed to mechanical ventilation (>48hours) were also more in this age group and this was found in accordance with earlier studies.⁷ The incidence of VAP was more in males (65.4%) compared to females (34.6%) which was similar to studies conducted by Sharma *et al*.⁷ Out of 107 VAP cases, 60 (56.1%) were categorized under early-onset VAP and 47 (43.9%) under late-onset VAP which was in concordance with studies conducted by Saravu *et al*.²⁰ Rates of polymicrobial infection vary widely. In our study only 6.5% of cultures were polymicrobial. In a study by Modi *et al*., 7.0% isolates were polymicrobial.¹⁴ Other studies have reported even higher rates.⁷ In this study (33.6%) *Pseudomonas aeruginosa*, (29.9%) *Acinetobacter baumannii* followed by 26.2% *K. pneumoniae* were the commonest isolates obtained in VAP cases (Table. 3), which were also reported as the commonest isolates by other studies.¹³⁻¹⁵ Few studies have shown gram positive cocci mainly *Staphylococcus aureus* as the most frequently isolated organism in VAP which is in contrast to our study.¹⁵ Golia *et al*., and co-workers also reported gram negative bacilli as the commonest etiological agents of late onset VAP which remains the same in our study also.⁷ In our study, maximum sensitivity was reported to imipenem (80.0%) followed by piperacillin -tazobactam (47.3%), amikacin (56.2%), and gentamicin (39.0%), minimum sensitivity was found to cefuroxime, ceftazidime and cefipime. All isolates were resistant to ampicillin, amoxycylav, 1st generation cephalosporins (Table 4). In our study, 27.1 % *Enterobacteriaceae* isolates were ESBL producers and *K. pneumoniae* was the commonest ESBL producer (Fig.2). Kucukates *et al*., also observed 21.1% ESBL prevalence rates in their study²⁰ while few studies shown higher ESBL rates.²¹ In this study, we observed 8.1% AmpC β -lactamase producers in enterobacteriaceae isolates with *K. pneumoniae* was the commonest AmpC producer (Fig.2).

Singhal *et al*²² also reported similar rates of AmpC production. Imipenem resistance was high in this study. Out of 21 Imipenem resistant isolates, 18 isolates were confirmed as MBL by imipenem-EDTA disk method. 17.1% *gram negative bacilli* were MBL producers were noted in our study. 34.4% of *Acinetobacter* species, 11.1% of the *Pseudomonas* and 11.5% *Klebsiella* isolates showed MDR (Fig.2), even to carbapenems, which is in concordance with other studies.^{7,23} Whereas certain studies reported higher incidence of meropenem resistance.^{21,24} All gram positive cocci in this study were 100% sensitive to linezolid and vancomycin. Four (44.4%) isolates of *S. aureus* were found to be sensitive to ceftoxitin. 55.5% of *Staphylococcus aureus* strains were MRSA (Table 5). The high incidence of MRSA in our study correlates well with studies done by Wattal *et al*,²¹ Joseph *et al*.⁵ The overall picture suggests that number of drug-resistant strains of various organisms is rising and is an important cause of VAP in our setting. ICU is considered as the 'Hotspot' for development of resistance. ESBL along with MBL is emerging in VAP infections. There is ample of evidences that ICUs are the epicentres of outbreaks of MDR pathogens.

CONCLUSION

This study showed that quantitative culture of ETA is a useful test for early diagnosis of VAP and provides specific knowledge of the causal agents associated with VAP along with their sensitivity pattern, which will help as an epidemiological marker for initial prophylactic and treatment planning for mechanically ventilated patients in our ICU setup. This study points towards a precarious situation in which our armamentarium of antibiotics is being rapidly depleting as most organisms are developed resistance to even the new generation antibiotics. This is an eye-opener for all healthcare providers working in the field of intensive care. This will help them to understand the microbiological spectrum of VAP and plan the management as well as preventive strategies accordingly.

REFERENCES

1. Charle MVP, Joshy M Easow, Joseph NM, Ravishankar M, Kumar S, Umadevi S. Incidence and risk factors of ventilator associated pneumonia in a tertiary care hospital. AMJ 2013; 6(4):178-182.
2. Coppadoro A, Bittner E, Berra L. Novel preventive strategies for ventilator-associated pneumonia. Crit Care. 2012; 16:210.
3. Strausbaugh LJ. Nosocomial Respiratory Infections. In: Mandell, Douglas, and Bennetts, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Elsevier Churchill Livingstone; 2000 (vol 2). P. 3020-28.
4. Rakshit P, Nagar VS, Deshpande AK. Incidence, clinical outcome, and risk stratification of ventilator-associated

- pneumonia: A prospective cohort study. *Indian J Crit Care Med.* 2005; 9:211-6.
5. Joseph NM, Sistla S, Dutta TK, Badhe AS, Rasitha D, Parija SC. Ventilator associated pneumonia in a tertiary care hospital pathogens. *J Infect Dev Ctries.* 2010; 218-25.
 6. Chastre J, Fagon JY. Ventilator associated pneumonia. *Am J Respir Crit Care Med.* 2001; 165:867-903.
 7. Golia S, KT Sangeetha And C Vasudha. Microbial profile of early and late onset ventilator associated pneumonia in the Intensive care unit of a tertiary care hospital in Banglore, India. *L. J Clin Diagn Res.* 2013; 7 (11) : 246-66.
 8. American thoracic society and the infectious diseases society of America. Guidelines for the management of adults with hospital acquired ventilator-associated and healthcare associated pneumonia. *Am J Respir Crit Care Med,* 2005; 171 (4): 388-416.
 9. Collee JG, Duguid JP, Fraser AG, Marmion BP, Simmons A. laboratory strategy in the diagnosis of infective syndromes. In: Collee JG, Marmion BP, Fraser AG, Simmons A, editors. Mackie and Mc Cartney's Practical Medical Microbiology. 14th ed. New Delhi: Reed Elsevier India Private Limited; 1996. p 53-94.
 10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 21th Informational Supplement (M100-S21). Wayne, Pa: Clinical and Laboratory Standards Institute; 2011.
 11. Forbes BA, Sahm DF, Weissfeld AS. Bailey and Scott's Diagnostic Microbiology, 12th ed. Missouri: Mosby Elsevier; 2007. P.811.
 12. Nagendra S, Bourbeau P, Brecher S, Dunne M, Larocco M, Doern G. Sampling variability i the microbiological evaluation of expectorated sputa and endotracheal aspirates. *J Clin Microbiolol* 2001; 39: 2344-7.
 13. Payal M, Tanuja J, Sandee N, Pandya N. A study on ventilator associated pneumonia in pediatric age group in a tertiary care hospital, vadodara. *national journal of medical research.* Volume 2, Issue 3, July – Sept 2012:318-21.
 14. Dey A, Bairy I. Incidence of multidrug-resistant organisms causing ventilator-associated pneumonia in a tertiary care hospital: A nine months' prospective study. *Ann Thorac Med* 2007; 2:52-7.
 15. Woske HJ, Roding T, Schulz I, Lode H. Ventilator-associated pneumonia in a surgical intensive care unit: epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling. *Critical Care* 2001;5:167-173.
 16. Jamaati HR, Malekmohammad, Hashemian MR, Nayebi M, Basharadz N. Ventilator associated pneumonia: Evaluation of etiology, microbiology and resistance patterns in a tertiary respiratory centre. *Tanaffos* 2010;9(1):21-7.
 17. Yehia Nasser AA, Haifaa H, El Sayed M, Al Asar. Nosocomial Infections in a Medical-Surgical Intensive Care Unit. *Med Princ Pract* 2008;17:373–7.
 18. Mukhopadhyay C, Bhargava A, Ayyagari A. Role of mechanical ventilation and development of multidrug organisms in hospital acquired pneumonia. *Indian J Med Res* 2003;118:229-35.
 19. Saravu Kavitha, Preethi V, Kumar Rishikesh, Guddattu Vasudev, Shastry Ananthkrishna and Mukhopadhyay Chiranjay. Determinants of ventilator associated pneumonia and its impact on prognosis: A tertiary care experience. *Indian J Criti Care Med.* 2013 Nov-Dec; 17 (6): 337-342.
 20. Kucukates E. Antimicrobial resistance among gram-negative bacteria isolated from intensive care units in a Cardiology Institute in Istanbul, Turkey. *Jpn J Inf Dis,* 2005;58(4):228-31.
 21. Wattal C, Goel N, Oberoi JK, Raveendran R, Datta S, Prasad KJ. Surveillance of multidrug resistant organisms in a tertiary care hospital in Delhi, India. *J Assoc Physician India* 2010;58:32-6.
 22. Singhal S, Mathur T, Upadhyay DJ, Chug S, Gaiind R, Rattan A. Evaluation of methods for Amp C β lactamase in gram negative clinical isolates from tertiary care. *Indian J Med Microbiol* 2005;23(2):120-4.
 23. Navneeth BV, Sridaran D, Sahay D, Belwadi MRS. A preliminary study on metallo- β -lactamases producing *Pseudomonas aeruginosa* in hospitalized patient. *Indian J Med Res* 2002;116:264-7.
 24. Gopalkrishnan R, Dorairajan S. Changing trends in antimicrobial susceptibility and hospital acquired infections over an 8 year period in a tertiary care hospital in relation to introduction of an infection control programme. *J Assoc Physician India,* 2010;58:25-31.